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Use of Cell Proliferation Data in Modeling
Urinary Bladder Carcinogenesis
by Samuel M. Cohen1 and Leon B. Ellwein2
A multistage, probabilistic, biologically based model of carcinogenesis has been developed
involving qualitative and quantitative aspects of the process. A chemical can affect the risk of
cancer by directly damaging DNA and /or increasing the number ofcell divisions during which
errors in DNAreplication can occur. Based on this model, carcinogens are classified as genotox-
ic versus nongenotoxic; nongenotoxic chemicals are further divided on the basis of whether or
not they act through a specific cell receptor. Nongenotoxic compounds, particularly those act-
ing through a nonreceptor mechanism, are likely to have dose and/or species-specific thresh-
olds. This classification also implies the existence ofchemicals that will be carcinogenic at high
doses in animal models, but because ofdose and/or mechanistic considerations, will not be car-
cinogenic to humans at levels ofexposure. N-[4-(5-nitro-2-furyl)-2-thiazolyljformamide (FANFT)
and 2-acetylaminofluorene (AAF) are classical genotoxic bladder carcinogens that also cause
proliferative effects at higher doses. Although there is an apparent no-effect level for the uri-
nary bladder carcinogenicity of these two compounds at low doses, in reality, DNA adducts
form at these low levels, and it is likely that there is a cancer effect (no threshold), but it is
below the level of detection of the bioassay. These conclusions are based on studies involving
multiple doses and time points in rodents, including results from the EDO,. Pellets implanted
directly into the rodent bladder lumen or calculi formed in the urine as a result of an adminis-
tered chemical cause abrasion of the urothelium, and a marked increase in cell proliferation
and cell number, and ultimately tumors. A threshold is readily definable based on physiologic,
chemical, and pharmacokinetic considerations. Sodium saccharin also produces bladder cancer
at high doses in rats, particularly males, if it is administered beginning at birth or earlier. The
mechanism appears to be related to the formation of a silicate precipitate and/or crystals
formed in the rat urine, which act as abrasives or cytotoxic materials, leading to increased cell
proliferation and ultimately tumors. Numerous other sodium salts have similar effects. This
effect is not observed in the mouse, hamster, or monkey, and epidemiological evidence suggests
that it does not occur in humans. Thus, for sodium saccharin, even in the susceptible species,
the rat, there appears to be a dose threshold, and extrapolation to humans appears inappropri-
ate based on mechanistic considerations.
A multistage, probabilistic, biologically based model
ofcarcinogenesis has been developed involving qualita-
tive and quantitative aspects of the process (1-3). The
risk of cancer can be affected by directly damaging
DNA and/or increasing the number of cell divisions
during which errors in DNA replication can occur.
Based on this model, carcinogens are classified as
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genotoxic versus nongenotoxic; nongenotoxic chemi-
cals are further divided on the basis of whether they
act through a specific cell receptor. Nongenotoxic com-
pounds, particularly those acting through a nonrecep-
tor mechanism, are likely to have dose and/or species-
specific thresholds. This classification also implies the
existence ofchemicals that will be carcinogenic at high
doses in animal models, but because of dose and/or
mechanistic considerations, will not be carcinogenic to
humans at anticipated levels ofexposure.
N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT)
is a bladder carcinogen in rats, mice, hamsters, and
dogs and behaves as a classic genotoxic carcinogen (4).
It is metabolically activated to a reactive intermediate
that binds to DNA, producing DNA adducts leading to
mutations and ultimately to cancer. If administered at
doses above 0.01% of the diet, nearly 100% of the ani-
mals develop bladder tumors, whereas at lower doses,COHENAND ELLWEIN
there are no tumors produced within 2 years, despite
the continuing presence of mutagenic activity in the
urine. In addition to the genotoxic effects of FANFT
metabolites interacting with DNA, FANFT adminis-
tration produces increased proliferation of the urothe-
lium, but only at the higher doses. Although the
absence oftumors below the 0.01% dose suggests a no-
effect level with respect to the bladder carcinogenicity
of FANFT, in reality, this is merely a reflection ofthe
limits of detection within the bioassay. The apparent
no-effect level corresponds to the dose at which a cellu-
lar proliferative response is no longer present for syn-
ergistic interaction with the genotoxic effects of the
compound. At doses where both effects are present, a
detectable incidence oftumors is produced.
When a low dose of FANFT (0.005%) is adminis-
tered simultaneously with a high dose of sodium sac-
charin (5%), there is a carcinogenic effect in the rat
bladder, whereas when these chemicals given sepa-
rately do not produce tumors (5). Sodium saccharin at
5% produces a proliferative response, which, in combi-
nation with the genotoxicity of FANFT even at a low
dose, is probably adequate to produce an increase in
bladder tumors within a2-yearexperiment.
Similarly, 2-acetylaminofluorene (AAF) produced
liver and bladder tumors when administered to mice.
Its metabolism is well known, with production ofreac-
tive intermediates that bind to DNA producing DNA
adducts, mutations, and ultimately tumors. In an
experiment involving greater than 24,000 mice (the
EDO, experiment), administration ofAAF at low doses
(30-150 ppm) produced dose-response relationships
that differed dramatically between the liver and blad-
der (6). In the liver, there was a detectable tumori-
genic effect at the lowest doses, whereas in the blad-
der, there was no detectable effect below a dose of 60
ppm. Apparently, the genotoxic effect ofAAF alone in
the liver is sufficient to produce a detectable level of
tumors because the doses used in the experiment were
insufficient to result in an increased proliferative
response in the liver.
In the bladder, however, a proliferative response is
produced at doses of 60 ppm and above, the doses at
which bladder tumors were detected. Although there
is clearly a genotoxic effect produced by AAF as evi-
denced by the presence of DNA adducts to doses as
low as 5 ppm of the diet (7), a detectable increase in
tumors coincides with the doses having increased cell
proliferation. In this regard, the dose-response rela-
tionship for the bladder with AAF is similar to that
with FANFT: Doses producing proliferative response
are adequate to generate a detectable incidence of
tumors within the bioassay time period, whereas at
lower doses, where only a genotoxic effect is present,
the expected incidence is below the level of detection
of the assay (8). With these genotoxic chemicals, the
measured no-effect level is not a true threshold, but
simply areflection ofthe detection limits ofthe assay.
In contrast to these examples ofgenotoxic chemicals,
other examples deal with cases where proliferative
events occur without accompanying genotoxicity. The
simplest of these is implantation of pelleted material
into the lumen ofthe bladder, which, depending on the
roughness of the surface of the pellet, produces abra-
sion of the urothelium, regenerative hyperplasia, and
ultimately tumors (3). The incidence of carcinoma
increases with time, as demonstrated by Jull (9) for
paraffin wax pellets: the incidence was 10.6% after
40-50 weeks, 26.8% after 70-80 weeks, and 53.8% after
100-110 weeks. A similar response is seen with other
implanted materials, such as cholesterol pellets, glass,
or stainless steel.
A similar phenomenon occurs with the production of
calculi in the urine, whether due to administration ofa
chemical that leads to the production of calculi (3) or
whether the necessary metabolic alterations are pro-
duced by other means, such as portacaval shunt (10),
which can also lead to calculus production. Whenever
calculi are produced, as with implanted pellets, there is
abrasion ofthe urothelium, increased cell proliferation,
and the increased risk of tumors. Calculi-producing
chemicals include uracil, melamine, calcium oxalate,
orotic acid, and glycine, as well as numerous others.
Administration of these chemicals at doses high
enough to produce calculi in the urine results in an
increased risk of bladder tumors. If lower doses are
administered, no calculi are generated and no bladder
tumors are produced. In contrast to the examples of
FANFT and AAF where the no-effect level for prolif-
erative response is not a no-effect threshold for tumor
production because of compound genotoxicity at low
doses, the no-effect dose for these compounds is truly a
threshold phenomenon. High-to-low dose extrapolation
for risk assessment is inappropriate in these cases;
what needs to be determined is the amount ofchemical
required to be ingested by the animal to produce cal-
culi, subsequently producing proliferative and tumori-
genic effects. At doses below which calculus formation
occurs, no tumors are expected. The threshold cannot
be determined by mathematical extrapolation but
must be determined on the basis of physical chemical,
pharmacokinetic, and physiological parameters.
A more subtle example occurs with sodium saccharin
and numerous other sodium salts, such as sodium
ascorbate, glutamate, erythorbate, citrate, aspartate,
and others (2,3,11). Again, similar to chemicals that
produce calculi where a high dose is required for the
production oftumors, these chemicals are nongenotox-
ic. At high doses, there is increased cell proliferation,
and at these doses, tumors occur. Although the details
have not been completely established (12), it appears
that the proliferative response occurs secondary to
cytotoxicity produced by silicate-containing precipitate
and/or crystals in the urine. The production of these
silicates requires large amounts of protein, which is
present in the rat, particularly the male. Consistent
with this, there is a male predominance of tumors in
the rat; the mouse, hamster, and monkey appear to be
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resistent to the effects of these chemicals. Epidemio-
logic evidence suggests that there is no tumorigenic
effect of sodium saccharin in humans (11), and prelimi-
nary studies also suggest that sodium saccharin inges-
tion does not produce increased cell proliferation ofthe
bladder (13). In male rats, the most susceptible species
and sex, a no-effect level appears at 1% of the diet. If
this represents atrue threshold, extrapolation to lower
doses is inappropriate, and expected exposure levels
by humans are unlikely to produce tumors. Similarly, if
the mechanism for the production of these silicates
occurs only in rats, and not in humans, interspecies
extrapolation to human risk based on studies in the rat
is inappropriate at any dose.
A similar difficulty occurs in estimating risk based
on studies with sodium ascorbate. Sodium ascorbate
affects the male rat in a fashion similar to sodium sac-
charin at comparable doses (14,15). If one calculates
risk in humans based on data from male rats, a 10 risk
in humans is estimated as approximately 3 mg/day.
This causes a serious problem because the minimum
daily human requirement for vitamin C to prevent
scurvy is 60 mg/day. In contrast, if one assumes a
threshold phenomenon at approximately 1% ofthe diet
in rats, the threshold for human consumption ofascor-
bate would be several orders of magnitude greater
than the required 60 mg/day. Further, if the effect is
truly confined only to the rat, then the cancer risk to
humans for vitamin C consumption with respect to
bladder cancer is zero, no matter what the dose.
The relationship of cell proliferation to carcinogene-
sis has produced confusion and seemingly conflicting
results, many of which can be explained with more
detailed examination of the biological phenomena
occurring in a given model system These are described
in greater detail elsewhere (3). Ofgreatest importance
with respect to risk assessment is that numerous
nongenotoxic chemicals produce their effects by
increasing cell proliferation, and it is likely, especially
for those chemicals not acting through a specific cell
receptor, that there is a threshold or a practical no-
effect level for humans. In addition, because of mecha-
nistic considerations, many of these chemicals will be
capable ofcausing cancer in a specific animal model but
would not be expected to have any tumorigenic effect
in humans.
Evaluation of a chemical as a potential carcinogenic
risk to humans using animal bioassays is based on two
important assumptions: a) If a chemical causes cancer
in mice and/or rats, it will cause cancer in humans
(interspecies extrapolation) and b) if a chemical causes
cancer at high doses, it will cause cancer at low doses
(dose extrapolation). For genotoxic chemicals such as
AAF and FANFT, these assumptions are likely to
hold. On the other hand, for chemicals such as sodium
saccharin and sodium ascorbate, neither of these
assumptions appear to be valid. With the greater
understanding we now have with respect to the mech-
anisms involved in chemical carcinogenesis and cancer
production in general, a more rational biological
approach to risk extrapolation based on data from
rodent bioassays is possible, supplementing blind, sim-
plistic, mathematical extrapolation driven by the
above two assumptions.
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